HVAX Technolog.

- The company plans to use the remaining Rs. 11 crores from the IPO proceeds for growth, cash flow support, and potential acquisitions or collaborations. - They have requested the merchant bankers to release these funds. - No explicit mention of any new fundraising through debt or equity at present or in the immediate future. - The focus is on leveraging existing IPO funds to sustain growth and possibly acquire or take stakes in like-minded companies over a year or two. - The company foresees growth funded primarily by the capital raised in the IPO rather than additional fundraising at this stage.

- HVAX Technologies plans to invest in enhancing in-house capabilities and R&D facilities, which will incur costs. - The company is actively evaluating like-minded companies for potential acquisitions or collaborations as part of its growth strategy. - Over the next 1 to 2 years, there may be acquisitions or taking substantial stakes in other companies. - The remaining Rs. 11 crores from IPO proceeds are requested to be released and will be used partly for cash flow and strategic investments. - The company aims to expand into new markets such as MENA, GCC, and Latin America, targeting larger and premium projects. - Investment in introducing IoT and AI into cleanroom systems is planned to enhance product offerings and operational efficiency.

- HVAX Technologies expects to grow revenues at a rate of 35% to 40% year-on-year into the near future. - The company is targeting niche segments such as biotechnology, healthcare (including hospitals and ICUs), semiconductors, solar, and data centers for diversification. - Growth is supported by expansion into new regions like MENA, GCC countries, and Latin America, known for premium and large-scale projects. - With strong presence in the African continent (16-17% revenue contribution), the company aims to capitalize on government PLI schemes promoting healthcare infrastructure. - The cleanroom industry is projected to grow at a CAGR of 6-7%, with the global market size at $8-10 billion. - HVAX plans to leverage operational excellence improvements and innovative technologies like IoT and AI for smart cleanrooms, enhancing its competitive edge. - Long-term revenue growth estimates range from 35% to 50%, with short-term growth around 35% to 40% for the next few years.

- HVAX Technologies expects a revenue growth of around 35% to 50% in the short term, with a more focused range of 35% to 40% annually over the next few years (Page 6, 4). - EBITDA margin showed a marginal improvement to 14.44% in FY '25 and management aims to maintain or slightly improve EBITDA margins going forward (Page 15, 17). - Net profit margin improved to 8.40% in FY '25, with net profit rising by nearly 30% YoY, indicating positive trends in profitability (Page 8). - The company anticipates tremendous growth in operational excellence supported by IPO funds, which will improve cash flow from operations and revenue churning (Page 9). - Entry into new sectors like hospitals, semiconductors, solar, and healthcare is expected to diversify revenue streams and support growth (Page 4, 7). - Overall, the company is confident of sustainable and strong profit growth supported by expanding markets and improved operational efficiencies.

- The company experiences a seasonal billing pattern with around 60-70% of billing occurring in the last two quarters, predominantly the last quarter. - Most billing (60-65%) happens in the last quarter of the financial year. - The order execution timelines vary by project: - Greenfield projects can take 1 to 2 years for completion. - Brownfield projects are completed typically within 3 to 9 months depending on scope and volume. - Retention money of around 5-10% is usually held, released after successful project completion, often backed by letters of credit. - Segment-wise details on execution periods, such as Pharma, Hospital, Data Center, Semiconductor, were being discussed but not fully disclosed in the excerpt. - The company is actively expanding into hospital projects, aiming to build design-build hospitals in collaboration with local biomedical engineers and government schemes. - The company expects growth in orders fueled by IPO proceeds and plans for acquisitions or strategic investments to boost orderbook.